1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1630
  5. Art Unit 1637
  6. Examiner Angell

Examiner Angell Jon E

1637-ANGELL-JON-E

Employment Information

Art Unit:1637 — Chemistry: molecular biology and microbiology
Group:1630 — Stem cells and cell culture and Nucleic Acid related therapy
Classes: 514 — Drug, bio-affecting and body treating compositions
536 — Organic compounds -- part of the class 532-570 series
424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
714 — Error detection/correction and fault detection/recovery
506 — Combinatorial chemistry technology: method, library, apparatus
800 — Multicellular living organisms and unmodified parts thereof and related processes
Phone:(571) 272-0756
Email:jone.angell@uspto.gov
Location:VA 22314
Title:Pat Examnr (Cbt-Biolgy)
Service:25 years
Grade:GS-14

Grant Rate and Difficulty Ranking

58
3-Year Grant rate: 72% over 316 cases
Difficulty: Medium
Difficulty Percentile: 58th

With Examiner Angell, you have a 72% chance of getting an issued patent by 3 years after the first office action. Examiner Angell is a medium examiner and in the 58th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Angell, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1637

Examiner Angell's grant rate is higher than that of Art Unit 1637 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Angell 1.4
Art Unit 1637 1.7

Interview Benefit

Grant Rate without Interview

Examiner Angell has granted 195 of 277 cases without any applicant-requested interviews for a grant rate of 70%.

Grant Rate with Interview

Examiner Angell has granted 31 of 39 cases with at least one applicant-requested interview for a grant rate of 79%.

Interview Benefit

With Examiner Angell, conducting an interview increases your chance of getting a patent granted by 13%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17537005 Exosomes And Micro-Ribonucleic Acids For Tissue Regeneration Rejection information available with a Premium Stats subscription. See our pricing. Patented View
17694316 Co-Delivery Of Tgf-B Sirna And Pdl1 Sirna To Treat Cancer Abandoned View
17920997 Methods And Compositions For Treating Inflammatory Conditions Associated With Infectious Disease Patented View
19098197 Methods And Compositions For Treating Inflammatory Conditions Associated With Infectious Disease Patented View
17808802 Compositions And Methods For The Treatment Of Hemoglobinopathies Patented View
17956884 Transmembrane Serine Protease 2 (Tmprss2) Irna Compositions And Methods Of Use Thereof Patented View
17823980 Angiopoietin-Like 3 (Angptl3) Irna Compositions And Methods Of Use Thereof Patented View
17923586 Utilizing Rna Interference Against Sars-Cov-2 Abandoned View
17912447 Antisense Rna For Treatment Of Sars-Associated Coronavirus Abandoned View
17627480 Novel Dna Aptamers And Use Thereof Patented View
17698917 Methods And Compositions For Modulating Gene Expression Patented View
17698912 Methods And Compositions For Modulating Gene Expression Patented View
17908933 Products For Suppressing Or Reducing The Expression Or Activity Of A Snorna And Uses Thereof In The Treatment Of Cancer Abandoned View
17530051 P-Ethoxy Nucleic Acids For Igf-1r Inhibition Patented View
17786796 An Ubiquitin Ligase Inhibitor For Use For Preventing And/or Treating A Disease Linked With Cerebral Hypoperfusion Abandoned View
18149251 Uses For Prevention Or Treatment Of Brain Diseases Using Microrna Abandoned View
18069490 Rnai Therapy For Hepatitis B Virus Infection Abandoned View
17706234 Methods And Compositions Of Short Small Hairpin Rnas And Micrornas For Wound Healing Abandoned View
18775784 Method Of Preparing Self-Circularized Rna Patented View
17916060 Double Stranded Rna Specifically Inhibiting Expression Of Il-23 And Pharmaceutical Composition Comprising Same Patented View
16647241 Rna Molecules Patented View
18069543 Genetic Modification Of Mammalian Cells To Confer Resistance To Csf1r Antagonists Patented View
18782965 Method For Treating C. Acnes Bacteria-Associated Diseases Patented View
17671048 Regulation Of Gene Expression By Aptamer-Mediated Modulation Of Alternative Splicing Patented View
18334632 Modulators Of Hsd17b13 Expression Patented View
17276105 Reducing Cd33 Expression To Selectively Protect Therapeutic Cells Patented View
17052945 Extrahepatic Delivery Patented View
17121835 Compositions And Methods For Nucleic Acid Transfer Patented View
17289767 Compositions And Methods For The Synthesis And Identification Of Covalent Aptamers Patented View
17515938 Molecular Pathogenesis Of Microcarcinoma Of The Thyroid Patented View
18899181 Compositions And Methods Of Generating Novel Amirna Patented View
17826387 Combinations Of Mrnas Encoding Immune Modulating Polypeptides And Uses Thereof Abandoned View
16968904 Gene Editing Using Homology-Independent Universal Genome Engineering Technology Patented View
17244835 Methods And Compositions For Treatment Of Interferon-Resistant Tumors Abandoned View
17258879 Compositions And Methods For Treating Endometriosis Patented View
17697319 Long Non-Coding Rna In Cancer Abandoned View
17663377 Therapeutic Inhibition Of Lactate Dehydrogenase And Agents Therefor Abandoned View
17818548 Transient Expression System For Rna, For Vaccination Abandoned View
17293153 Encapsulated Polynucleotides And Methods Of Use Abandoned View
18050760 Compositions And Methods For The Treatment Of A Beta-Catenin-Associated Disease Or Disorder Abandoned View
17849513 Monocyte And Macrophage Binding Aptamers And Their Application Patented View
17834988 Compositions And Methods For Inhibiting Gene Expression Of Alpha-1 Antitrypsin Patented View
16316378 Collagen-Mimetic Peptide Mediated Delivery Of Nucleic Acid Carriers For Efficient Delivery From Collagen Patented View
17156348 Treatment Of Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, And Liver Fibrosis Abandoned View
17251200 Therapeutic Agent For Alzheimer's Disease Abandoned View
17441895 Oligonucleotide Interference Treatments Of Prostate Cancer Patented View
18361363 Modified Short Interfering Nucleic Acid (Sina) Molecules And Uses Thereof Patented View
17264727 Method Of Identifying Or Producing An Aptamer For A Denatured Peptide Or Protein Abandoned View
17385560 Methods And Compositions For Ex Vivo Expansion Of Very Small Embryonic-Like Stem Cells (Vsels) Patented View
17666341 Antisense Oligonucleic Acid Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.